146 related articles for article (PubMed ID: 17383882)
1. Selective inhibition of the interaction of C1q with immunoglobulins and the classical pathway of complement activation by steroids and triterpenoids sulfates.
Bureeva S; Andia-Pravdivy J; Symon A; Bichucher A; Moskaleva V; Popenko V; Shpak A; Shvets V; Kozlov L; Kaplun A
Bioorg Med Chem; 2007 May; 15(10):3489-98. PubMed ID: 17383882
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells.
Duvall MR; Hwang HY; Boackle RJ
Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684
[TBL] [Abstract][Full Text] [Related]
3. Complement C1q-target proteins recognition is inhibited by electric moment effectors.
Roumenina L; Bureeva S; Kantardjiev A; Karlinsky D; Andia-Pravdivy JE; Sim R; Kaplun A; Popov M; Kishore U; Atanasov B
J Mol Recognit; 2007; 20(5):405-15. PubMed ID: 17929239
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of the early phase of complement activation.
Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.
Nauta AJ; Bottazzi B; Mantovani A; Salvatori G; Kishore U; Schwaeble WJ; Gingras AR; Tzima S; Vivanco F; Egido J; Tijsma O; Hack EC; Daha MR; Roos A
Eur J Immunol; 2003 Feb; 33(2):465-73. PubMed ID: 12645945
[TBL] [Abstract][Full Text] [Related]
6. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum.
Walpen AJ; Laumonier T; Aebi C; Mohacsi PJ; Rieben R
Xenotransplantation; 2004 Mar; 11(2):141-8. PubMed ID: 14962276
[TBL] [Abstract][Full Text] [Related]
8. [Effect of medicinal preparations on the complement: inhibition of subcomponent C1q binding to a target].
Bichucher AM; Kozlov LV
Eksp Klin Farmakol; 2007; 70(6):25-8. PubMed ID: 18318191
[TBL] [Abstract][Full Text] [Related]
9. Complement activation and disease: protective effects of hyperbilirubinaemia.
Basiglio CL; Arriaga SM; Pelusa F; Almará AM; Kapitulnik J; Mottino AD
Clin Sci (Lond); 2009 Oct; 118(2):99-113. PubMed ID: 19807696
[TBL] [Abstract][Full Text] [Related]
10. Activation of classical pathway of complement cascade by soluble oligomers of prion.
Dumestre-Pérard C; Osmundson J; Lemaire-Vieille C; Thielens N; Grives A; Favier B; Csopaki F; Jamin M; Gagnon J; Cesbron JY
Cell Microbiol; 2007 Dec; 9(12):2870-9. PubMed ID: 17991046
[TBL] [Abstract][Full Text] [Related]
11. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation.
Goslings WR; Prodeus AP; Streilein JW; Carroll MC; Jager MJ; Taylor AW
Invest Ophthalmol Vis Sci; 1998 May; 39(6):989-95. PubMed ID: 9579478
[TBL] [Abstract][Full Text] [Related]
12. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin.
Matsushita M; Matsushita A; Endo Y; Nakata M; Kojima N; Mizuochi T; Fujita T
Proc Natl Acad Sci U S A; 2004 Jul; 101(27):10127-31. PubMed ID: 15218103
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of the classical complement pathway by C1q-binding peptides.
Roos A; Nauta AJ; Broers D; Faber-Krol MC; Trouw LA; Drijfhout JW; Daha MR
J Immunol; 2001 Dec; 167(12):7052-9. PubMed ID: 11739526
[TBL] [Abstract][Full Text] [Related]
14. Hemolytic assay for the measurement of functional human mannose-binding lectin: a modification to avoid interference from classical pathway activation.
Herpers BL; de Jong BA; Dekker B; Aerts PC; van Dijk H; Rijkers GT; van Velzen-Blad H
J Immunol Methods; 2009 Mar; 343(1):61-3. PubMed ID: 19171151
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of classical pathway of complement activation with negative charged derivatives of bisphenol A and bisphenol disulphates.
Bureeva S; Andia-Pravdivy J; Petrov G; Igumnov M; Romanov S; Kolesnikova E; Kaplun A; Kozlov L
Bioorg Med Chem; 2005 Feb; 13(4):1045-52. PubMed ID: 15670912
[TBL] [Abstract][Full Text] [Related]
16. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation.
Groeneveld TW; Ramwadhdoebé TH; Trouw LA; van den Ham DL; van der Borden V; Drijfhout JW; Hiemstra PS; Daha MR; Roos A
Mol Immunol; 2007 Jul; 44(14):3608-14. PubMed ID: 17448537
[TBL] [Abstract][Full Text] [Related]
17. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
18. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q.
Ying SC; Gewurz AT; Jiang H; Gewurz H
J Immunol; 1993 Jan; 150(1):169-76. PubMed ID: 8417122
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy.
Oberkersch R; Attorresi AI; Calabrese GC
Thromb Res; 2010 May; 125(5):e240-5. PubMed ID: 20035973
[TBL] [Abstract][Full Text] [Related]
20. Steroids and triterpenes from the fruit bodies of Ganoderma lucidum and their anti-complement activity.
Seo HW; Hung TM; Na M; Jung HJ; Kim JC; Choi JS; Kim JH; Lee HK; Lee I; Bae K; Hattori M; Min BS
Arch Pharm Res; 2009 Nov; 32(11):1573-9. PubMed ID: 20091270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
